Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Nov 25

PMID 38001897

Authors

Yousef M Al-Saraireh

Fatemah O F O Alshammari

Omar H Abu-Azzam

Saed M Al-Dalain

Yahya M Al-Sarayra

Mansour Haddad

Hafiz Makeen

Aiman Al-Qtaitat

Mohammad Almermesh

Sameeh A Al-Sarayreh

Affiliations

Soon will be listed here.

Abstract

Over the past decade, there have been significant developments in treatment for ovarian cancer, yet the lack of targeted therapy with few side effects still represents a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs and has a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial to understanding the pathophysiology of ovarian cancer since many isoforms are essential to the metabolism of xenobiotics and steroid hormones, which drive the disease's development. To the best of our knowledge, no review articles have documented the intratumoral expression of CYPs and their implications in ovarian cancer. Therefore, the purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with the effects of CYP polymorphisms on chemotherapy metabolism. Finally, we discuss opportunities to exploit metabolic CYP expression for the development of novel therapeutic methods to treat ovarian cancer.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.

The deregulation of arachidonic acid metabolism in ovarian cancer.

Xia Q, Gao W, Yang J, Xing Z, Ji Z Front Oncol. 2024; 14:1381894.

PMID: 38764576 PMC: 11100328. DOI: 10.3389/fonc.2024.1381894.

References

Huang M, Chen Q, Xiao J, Zhao X, Liu C . CYP1A1 Ile462Val is a risk factor for ovarian cancer development. Cytokine. 2012; 58(1):73-8. DOI: 10.1016/j.cyto.2011.12.025. View

Imaoka S, Yoneda Y, Sugimoto T, Hiroi T, Yamamoto K, Nakatani T . CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun. 2000; 277(3):776-80. DOI: 10.1006/bbrc.2000.3740. View

Fortin S, Charest-Morin X, Turcotte V, Lauvaux C, Lacroix J, Cote M . Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells. J Med Chem. 2017; 60(12):4963-4982. DOI: 10.1021/acs.jmedchem.7b00343. View

Capper C, Rae J, Auchus R . The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. Horm Cancer. 2016; 7(3):149-64. PMC: 4860032. DOI: 10.1007/s12672-016-0259-0. View

Freedman R, Wang E, Voiculescu S, Patenia R, Bassett Jr R, Deavers M . Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res. 2007; 13(19):5736-44. DOI: 10.1158/1078-0432.CCR-07-0583. View

Leung Y, Lau K, Mobley J, Jiang Z, Ho S . Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005; 65(9):3726-34. DOI: 10.1158/0008-5472.CAN-04-3771. View

Rodriguez M, Potter D . CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013; 11(7):780-92. PMC: 3720830. DOI: 10.1158/1541-7786.MCR-12-0675. View

Zollner A, Dragan C, Pistorius D, Muller R, Bode H, Peters F . Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem. 2008; 390(4):313-7. DOI: 10.1515/BC.2009.030. View

Stevison F, Jing J, Tripathy S, Isoherranen N . Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer. Adv Pharmacol. 2015; 74:373-412. PMC: 4859867. DOI: 10.1016/bs.apha.2015.04.006. View

10.

Downie D, McFadyen M, Rooney P, Cruickshank M, Parkin D, Miller I . Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11(20):7369-75. DOI: 10.1158/1078-0432.CCR-05-0466. View

11.

Al-Saraireh Y, Alshammari F, Youssef A, Al-Tarawneh F, Al-Sarayreh S, Almuhaisen G . Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers. Breast Cancer (Dove Med Press). 2021; 13:565-574. PMC: 8502010. DOI: 10.2147/BCTT.S329770. View

12.

Klose T, Blaisdell J, Goldstein J . Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol. 1999; 13(6):289-95. DOI: 10.1002/(sici)1099-0461(1999)13:6<289::aid-jbt1>3.0.co;2-n. View

13.

Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S . A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012; 137(6):918-30. DOI: 10.1309/AJCPF3QWIG8FWXIH. View

14.

DeLoia J, Zamboni W, Jones J, Strychor S, Kelley J, Gallion H . Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol Oncol. 2007; 108(2):355-60. DOI: 10.1016/j.ygyno.2007.10.029. View

15.

Kwon Y, Baek H, Ye D, Shin S, Kim D, Chun Y . CYP1B1 Enhances Cell Proliferation and Metastasis through Induction of EMT and Activation of Wnt/β-Catenin Signaling via Sp1 Upregulation. PLoS One. 2016; 11(3):e0151598. PMC: 4794175. DOI: 10.1371/journal.pone.0151598. View

16.

Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H . Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012; 264(1):73-83. PMC: 3439529. DOI: 10.1016/j.taap.2012.07.019. View

17.

Delort L, Chalabi N, Satih S, Rabiau N, Kwiatkowski F, Bignon Y . Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res. 2008; 28(5B):3079-81. View

18.

Goodman M, Tung K, McDuffie K, Wilkens L, Donlon T . Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Nutr Cancer. 2003; 46(1):23-9. DOI: 10.1207/S15327914NC4601_03. View

19.

Aktas D, Guney I, Alikasifoglu M, Yuce K, Tuncbilek E, Ayhan A . CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol. 2002; 86(2):124-8. DOI: 10.1006/gyno.2002.6720. View

20.

Marsh S, Paul J, King C, Gifford G, McLeod H, Brown R . Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007; 25(29):4528-35. DOI: 10.1200/JCO.2006.10.4752. View